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Dietary supplements, including those containing botanical ingredients and botanical-
derived compounds, have been marketed to consumers globally for many decades. 
However, the legislative framework for such products remains inconsistent across 
jurisdictions internationally. A common problem, concerning these nutraceutical products, 
is deficient information and lack of data for assessing the hazards posed to human health. 
The main objective is to explore the use of in silico tools in a risk assessment context of 
nutraceutical product, to relate properties of the molecular structure to the toxic effect of 
the chemical substance, by using principles and methods of computational chemistry. 
Further consideration of the actual impact of adverse events arising from nutraceutical 
food supplement usage will be helpful in guiding such issue as a potential for 




A nutraceutical can be defined as a food or food product 
that is reported to provide medical benefits, such as 
prevention and treatment of diseases. It is produced 
under Good Manufacturing Practice (GMP) conditions 
and may range from isolated nutrients, dietary 
supplements and specific diets to genetically engineered 
foods, herbal products and process food (Mohammad et 
al., 2015). Example of nutraceutical products includes 
vitamins, mineral, herbal supplements, a semi-purified 
substance from natural sources, plant extract, functional 
food and beverages, probiotics and topical application 
for skincare (Labadi, 2017).  The illness that is normally 
administered by nutraceutical products is anti-arthritic, 
cold and cough, prevention of certain cancer, diabetes, 
sleep disorders, hypertension and osteoporosis (Pandey 
et al., 2010). Nutraceutical can be divided into three 
main segments, which are natural products, dietary 
supplements and functional foods. A nutraceutical 
products segment with rapid growth due to the high level 
of interest and demand by the consumer (Nutrition 
Business Journal, 2006). They are often seen as more 
flattering as compared to pharmaceutical drugs as they 
are being seen as more natural and likely to incur 
minimum side effects (Teschke et al., 2013). Besides, the 
availability of the nutraceutical products over the counter 
of the supermarket, health food shop and pharmacies 
make it easier to be reached by consumers (Posadzki et 
al., 2013).  
High cost incurs by modern disease treatment make 
the consumer look for alternative or complementary 
beneficial product such as the appealing nutraceutical 
product. Recently, nutraceutical product has been 
scientifically supported with nutritional and medical 
evidence and become a potentially effective alternative 
(Dillard and German, 2000). A sturdy regulation and 
assessment need to be developed and implemented to 
give impact on consumer and to standardise the 
nutraceutical compound. Besides, the requirement of the 
execution of clinical studies, provide a basis for health 
claims, commercial positioning and functional claims of 
nutraceutical products should be evidence-based that 
supported by convincing scientific data from well design 
studies. Moreover, nutraceutical products are often taken 
as “self-medication” without concern from the medical 
doctor regarding any diseases that may lead to 
uncertainty in the observed effects. Therefore, there 
should be special aspects that need to be considered 
instead of a basic design study that is similar to that of 
pharmaceutical studies (Gao et al., 2014).  
A considerably high number of cases that have been 
reported on the adverse effects of nutraceutical products 
that pose a real risk to the public (Rocha et al., 2016). 
The arising issue recently was the adulteration of 
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nutraceutical products with pharmaceutical substance 
and accidental replacement of botanicals with some other 
toxic plant or substance (Stegelmeier et al., 2015). 
Besides, compounds such as alkylbenzenes, estragole 
and methyl eugenol that are naturally contained in some 
botanicals are found to be genotoxic and 
hepatocarcinogenic based on the animal study done by 
Scientific Committee on Food European Commission 
(SCF EC., 2001). Reports on human studies associated 
with the severity of the effect of the consumption of 
botanicals range that caused an elevation in blood 
pressure, acute liver failure requiring liver 
transplantation, tumours of the urinary tract and even 
death (Fujita et al., 2007; Nortier et al., 2009). 
Unravelling the kinetic profiles and rectifying the 
bioavailability of nutraceutical properties and nutritional 
compounds posture some challenge especially in dealing 
with complex mixture derived from herbal plants. The 
main problem is to characterise the exact bioactive 
compound that regulates the bioactive intake. The 
difficulty is due to the variation in the plant. The 
variation further complicates the interpretation of 
different bioactive within the botanical compound in 
nutraceutical that may exert either antagonistic or 
synergistic interaction (Schmitt and Farro, 2013).  
Animal testing has been used to provide 
toxicological information, but in addition to the ethical 
consideration, it is both expensive and time consuming. 
Alternatives to animal data, i.e., non-testing data is 
therefore desirable and is highlighted to promote 
alternative methods for the assessment of hazards 
substances. Non-testing data (as known as non-animal-
testing data) includes in vitro data but can also be 
generated using in silico tools. In silico means within 
computer, and the term ‘in silico tools’ is collectively 
used to refer to methods as structure reactivity 
relationships (SARs), quantitative structure-activity 
relationships (QSARs) (Puzyn et al., 2010) and network 
pharmacology.  
With the continuous maturation of computer 
technology, increase use of in silico tools for non-testing 
data as structure-activity relationships (SARs), 
quantitative structure-activity relationships (QSARs), 
and pathway and network analysis. This led to the rapid 
elucidation of the complex relationships between 
compounds and their various target activity (Rubio-Perez 
et al., 2015). The main objective of this review is to 
explore the use of in silico tools in a risk assessment 
context of nutraceutical products. In particular, this 
review attempted to relate properties of the molecular 
structure to the toxic effect of the chemical substance, by 
using principles and methods of computational chemistry 
and determine the impact of adverse events arising from 
nutraceutical food supplement.  
  
2. Risk assessment and regulation 
The assessment criteria for the nutraceutical products 
are generally similar between some country such as 
Australia, USA and Europe (EU). Particularly, 
information related to the requirement of basic 
information of the botanical substance and description of 
the botanical substance and description of the 
manufacturing process (Low et al., 2017). However, 
jurisdiction regarding the specific toxicology data 
requirement, clinical trial data and adverse reaction 
report of nutraceutical product are mostly diversified. An 
example can be seen in term of requirement on specific 
toxicological studies.  Food and Drug Administration 
(FDA) and Therapeutic Goods Administration (TGA) 
describe the necessary toxicity studies in detail as 
compared to the European Food Safety Authority 
(EFSA) which is comparatively brief. FDA even take an 
initiative to come out with a “Safety Testing 
Recommendation Matrix” that has been a good reference 
for business operations as it recommends a different 
combination of toxicology data based on the historical 
used of the ingredients to determine the possible toxicity 
of their products. This matrix helps the business operator 
in a way of reducing the cost and the hassle of 
conducting the toxicity study (Center for Drug 
Evaluation and Research (CDER) FDA, 2008).  
Data on clinical trials are required by TGA guideline 
for risk assessment as TGA regulates the nutraceutical 
product as complementary medicine rather than food 
supplement (TGA, 2016).  EFSA, on the other hand, 
does not acquire such data. This is not also obligatory for 
FDA to provide the clinical trials data; however, they 
require to at least have a tolerability study on adsorption, 
distribution, metabolism and excretion (ADME) studies 
to determine the safety margin for one product (Center 
for Drug Evaluation and Research (CDER) FDA, 2008).    
The development of extraction technologies poses a 
new risk related to botanical through the dynamic of 
economically motivated fraud. Moreover, there are some 
aspects that have not been considered in the guideline for 
risk and safety assessment of nutraceutical products. 
Despite the uncertainty of the authentication and 
differences in regulation, the global nutraceutical market 
has been valued at USD 109.8 billion and expected to 
grow to an expected value of USD 180 billion by 2020 
(Persistence Market Research, 2015). Therefore, the 
current issues should set the direction in the nutraceutical 
field that highlight the evidence-based nutraceutical 
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health.   
 
3. SAR and QSAR 
SAR analysis is the identification of chemical 
properties or specific fragments of the molecular 
structure involved in an observed or measured effect. A 
QSAR model approximates the relationship between the 
molecular structure and biological activity in a 
quantitative manner (Eriksson et al., 2003). The QSAR 
model can be used to determine SAR. The quantitative 
correlation was established, the biological or toxicology 
activity, as well as the chemical and structural properties, 
were defined with numerical values. The outcome of 
biochemical and toxic effects of substances was 
measured in vitro assays. QSAR modelling involves a set 
of chemical structures that are assumed to act through 
the same mechanism of action. The development of 
QSAR model then follows a stepwise process illustrated 
in Figure 1. 
The organisation for economic cooperation and 
development (OECD) had outlined the principle for 
QSAR validation (OECD, 2007) for regulatory 
acceptability. According to these principles, a QSAR 
model should be associated with 1) a defined endpoint, 
2) an unambiguous algorithm, 3) a defined domain of 
applicability, 4) appropriate measures of goodness-of-fit, 
robustness and predictivity, and if possible, 5) a 
mechanistic interpretation. The principle aims to ensure 
that selection of the chemical descriptors is well-
considered concerning the endpoint of the investigation, 
and that any association found between the chemical 
descriptors and the endpoint is documented (OECD, 
2007). 
 Toxicity of a substance is ruled by their chemical 
structure where it has a direct relationship with the 
properties and thus toxicity of a substance. The 
relationship may be statistically calculated to describe 
the molecular properties of a substance base on the 
descriptor of a compound structure (Deeb and Goodarzi, 
2012).  The first work on QSAR was published by 
Hansch et al. (1962) that developed the relationship 
between biological activity with the descriptor of 
compound structure.     
    The study on the in silico quantitative structure 
toxicity relationship has been conducted by Pasha et al. 









Figure 1. Stepwise QSAR/ in silico approach  
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aromatic nitro compounds with similar structures were 
assayed with different targets. Based on the activities 
determined by the assays, two dimensional (2D) 
quantitative structure-toxicity relationship models were 
developed using twenty chosen topological descriptors. 
Then, the author applied the multiple linear regression 
analysis to associate the variation of molecular properties 
with toxicity. From the study, a strong framework for 
understanding the link between molecular toxicity with 
the aromatic nitro compounds structure has been 
proposed by the authors. In conclusion, the molecular 
size, branching and molecular flexibility strongly 
associated with the toxicity of the nitro compound based 
on the best correlation between topological descriptor 
and molecular toxicity in the model.    
 
4. Pathway and network analysis 
In recent years, with an increasingly in-depth 
understanding of the structure and function of 
compounds, a series of new technologies and methods 
have been applied to the development of medicinal 
plants (Yi et al., 2016). The verification of the in vivo 
and in vitro pharmacological experiments can be 
established by accurately predict a large number of 
chemical compounds. Based on the prediction, a 
significant improvement in the efficiency of evaluating 
the chemical activities of nutraceutical product can 
develop a quick and convenient pathway. 
The continuous maturation of computer technology 
nowadays, enable the utilization of the computer 
platform to calculate the combinations of simulated 
compound and target to be more efficient and accurate. 
In addition, the development of network pharmacology 
technologies has enabled the rapid elucidation of the 
complex relationships between compounds and their 
various activity targets (Rubio-Perez et al., 2015). 
The complexity of network pharmacology 
technology is reflected not only in the composition of the 
chemical constituents but also embodied in the network 
of relationships between the prescription and the human 
body and the exertion of pharmacological effects through 
multiple channels, multiple targets and the overall 
regulatory mechanism (Zhang et al., 2016). 
 Yi et al. (2018), have developed a set of effective 
and accurate methods to unravel the pharmacological 
effect of plant materials and predict the bioactive 
compound. The first crucial part is to verify the research 
significant of the plants. There are three categories of 
plants the first category is the plant that is a common 
herbs with complex mechanism followed by the herbs 
with long history traditional usage and the last category 
is the herbs with known traditional usage but now with 
new utilization. Next is to construct and organize the 
natural product database. Then, proceed with the pre-
treatment of the compounds (ADME/T, prediction and 
exclusion of false-positive compounds followed by the 
important technique which is the in silico virtual 
screening. Next step is the analysis of the group of 
targets identified. Lastly, the construction of network 
relationship between medicinal plants, natural 
compound, biological targets, signaling pathways and 
disease. Abiding to this method enables the authors to 
predict the potential pharmacological activities of the 
bioactive compounds in medicinal plant.      
 
5. Conclusion 
The alternative strategies for the assessment of 
hazards to complement in vitro and in vivo studies for 
nutraceutical products have been explored. The potential 
of using different in silico methods for this purpose has 
been investigated and QSAR models have been studied. 
Information contained into diverse datasets of 
nutraceutical product was searched with  SAR  and  
QSAR  methods. A wide-ranging complete technical 
route that utilizes a series of in silico approaches to 
reveal the pharmacological basis of the effects of 
medicinal plants were proposed. This in silico 
methodology can resolve the status of medicinal plants 
that are difficult to study on a practical level and can 
predict and clarify the mechanisms of the active 
ingredients in nutraceutical product. Through more 
practical researches and development examples to 
upgrade the entire process of in silico methodology, we 
believe that in the future, this methodological process 
will enable the discovery of new active compound more 
efficiently, accurately and quickly. This methodology 
will be more widely used in future work on revealing and 
predicting the basis of nutraceutical materials. 
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